Attached files
| file | filename |
|---|---|
| 10-K - KURA-10K-20161231 - Kura Oncology, Inc. | kura-10k_20161231.htm |
| EX-32.1 - EX-32.1 - Kura Oncology, Inc. | kura-ex321_8.htm |
| EX-31.2 - EX-31.2 - Kura Oncology, Inc. | kura-ex312_6.htm |
| EX-31.1 - EX-31.1 - Kura Oncology, Inc. | kura-ex311_12.htm |
| EX-10.12 - EX-10.12 - Kura Oncology, Inc. | kura-ex1012_1160.htm |
| EX-10.11 - EX-10.11 - Kura Oncology, Inc. | kura-ex1011_49.htm |
| EX-10.10 - EX-10.10 - Kura Oncology, Inc. | kura-ex1010_48.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-3 No. 333-210614) of Kura Oncology, Inc., and |
|
|
2. |
Registration Statement (Form S-8 No. 333-210260) pertaining to the Amended and Restated 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan of Kura Oncology, Inc.; |
of our report dated March 14, 2017, with respect to the financial statements of Kura Oncology, Inc., included in this Annual Report (Form 10-K) of Kura Oncology, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
San Diego, California
March 14, 2017